GlassScriptPhysician profile
Scott N Harder
NPI 1932166154
$5,192.15
in general payments reported to CMS, 2019-2025
47 companies · $731 in 2025
The $731 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $733 · 2021: $950 · 2022: $932 · 2023: $781 · 2024: $720 · 2025: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,232.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $707.63 | 2020-2025 | |
| Novo Nordisk INC | $652.03 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $498.42 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Astellas Pharma US INC | $479.03 | 2019-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $426.19 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $406.13 | 2022-2025 | |
| Pfizer INC. | $162.82 | 2019-2025 | |
| Amgen INC. | $150.33 | 2019-2024 | Evenity, Prolia |
| Allergan, INC. | $149.76 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $109.60 | 2022-2024 | Quviviq |
| Abbott Laboratories | $97.51 | 2021-2023 | Freestyle Libre 2 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $97.50 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $90.70 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $89.39 | 2020-2022 | |
| Eisai INC. | $77.05 | 2020-2021 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Harder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.